CN115634250A - She medicine phlegm-reducing ultrafine powder patch and preparation method thereof - Google Patents
She medicine phlegm-reducing ultrafine powder patch and preparation method thereof Download PDFInfo
- Publication number
- CN115634250A CN115634250A CN202211346714.9A CN202211346714A CN115634250A CN 115634250 A CN115634250 A CN 115634250A CN 202211346714 A CN202211346714 A CN 202211346714A CN 115634250 A CN115634250 A CN 115634250A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- phlegm
- ultra
- fine powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a she medicine phlegm reducing ultra-fine powder patch, which comprises the following medicinal components in parts by weight: 45-55 parts of herb tea (she), 45-55 parts of Chinese prickly ash (she), 10-20 parts of ephedra, 25-35 parts of almond, 10-20 parts of ginger processed pinellia tuber, 10-20 parts of Chinese lute leaf, 5-15 parts of borneol and 5-15 parts of liquorice; the she medicine phlegm-resolving formula submicron powder acupoint ultrasonic penetration can obviously improve the traditional Chinese medicine syndrome integral of a patient with phlegm-heat obstructing lung type wind-warm lung-heat, effectively reduce the CPIS score of the lung infection of the patient and related inflammatory indexes (N%, CRP and PCT), effectively improve the clinical curative effect, and is worthy of clinical popularization and use.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a she medicine phlegm-reducing ultra-fine powder patch.
Background
The symptoms of phlegm-heat obstructing lung type wind-warm lung-heat disease are as follows: persistent high fever, cough, yellow and thick sputum or iron rust, chest pain, shortness of breath, thirst, dysphoria, yellow and red urine, dry stool or constipation, red tongue with yellow coating, and surging and rapid or slippery pulse.
The disease is treated by western medicines, a better treatment effect can be achieved by a plurality of treatment courses, and the recovery of a patient is slow, so that the she medicine phlegm-reducing submicron powder patch with the auxiliary treatment effect is needed to be provided to improve the clinical treatment effect.
Disclosure of Invention
The invention aims to provide a she medicine phlegm-reducing ultra-fine powder patch to solve the problems in the background technology.
In order to achieve the purpose, the invention provides the following technical scheme:
the she medicine phlegm reducing formula submicron powder patch comprises the following medicine components in parts by weight: 45-55 parts of she tea, 45-55 parts of Chinese melastoma, 10-20 parts of ephedra, 25-35 parts of almond, 10-20 parts of ginger processed pinellia, 10-20 parts of Chinese lute leaf, 5-15 parts of borneol and 5-15 parts of liquorice.
The she medicine phlegm-reducing ultra-fine powder patch comprises the following medicine components in parts by weight: 50 parts of herb tea (she), 50 parts of herba rhodomyrti (she), 15 parts of ephedra, 30 parts of almond, 15 parts of rhizoma pinelliae preparata, 15 parts of Chinese lute leaf, 10 parts of borneol and 10 parts of liquorice.
The she-medicine phlegm-reducing submicron powder patch is prepared by drying the medicines of the she-medicine phlegm-reducing submicron powder patch at the temperature of 60 ℃, carrying out superfine grinding, mixing, blending 45 parts by weight of honey, 50 parts by weight of water and 0.95 part by weight of herb tea oil into ointment, coating the ointment on an ultrasonic lead-in cotton piece before use, and preparing the she-medicine phlegm-reducing submicron powder patch.
The diameter of the she medicine phlegm-reducing ultra-fine powder patch is 3.7cm, the thickness of the she medicine phlegm-reducing ultra-fine powder patch is 2mm, and the weight of each she medicine phlegm-reducing ultra-fine powder patch traditional Chinese medicine ointment is 4g.
The beneficial technical effects of the invention compared with the prior art are that,
the she medicine phlegm-resolving formula submicron powder acupoint ultrasonic penetration can obviously improve the traditional Chinese medicine syndrome integral of a patient with phlegm-heat obstructing lung type wind-warm lung-heat, effectively reduce the CPIS score of the lung infection of the patient and related inflammatory indexes (N%, CRP and PCT), effectively improve the clinical curative effect, and is worthy of clinical popularization and use.
Detailed Description
The present invention will be further described with reference to the following examples.
The she medicine phlegm reducing formula submicron powder patch comprises the following medicine components in parts by weight: 45-55 parts of she tea, 45-55 parts of Chinese melastoma, 10-20 parts of ephedra, 25-35 parts of almond, 10-20 parts of ginger processed pinellia, 10-20 parts of Chinese lute leaf, 5-15 parts of borneol and 5-15 parts of liquorice.
The she medicine phlegm-reducing ultra-fine powder patch comprises the following medicine components in parts by weight: 50 parts of herb tea (she), 50 parts of herba rhodomyrti (she), 15 parts of ephedra, 30 parts of almond, 15 parts of rhizoma pinelliae preparata, 15 parts of Chinese lute leaf, 10 parts of borneol and 10 parts of liquorice.
The herbal tea for feeding in the prescription is a special Chinese medicinal material of she nationality and is currently recorded in 2015 edition 'Zhejiang province Chinese medicine processing standard'.
The she-medicine phlegm-reducing submicron powder patch is prepared by drying the medicines of the she-medicine phlegm-reducing submicron powder patch at the temperature of 60 ℃, carrying out superfine grinding, mixing, blending 45 parts by weight of honey, 50 parts by weight of water and 0.95 part by weight of herb tea oil into ointment, coating the ointment on an ultrasonic lead-in cotton piece before use, and preparing the she-medicine phlegm-reducing submicron powder patch.
The product name of the ultrasound-introduced cotton sheet is a physical therapy electrode, and the ultrasound-introduced cotton sheet is purchased from medical equipment Limited of Zhongxin, henan province, and has the model number of ZLD-002.
The superfine grinding is an operation technology which utilizes a mechanical or fluid power method to overcome the internal cohesive force of a solid and break the solid, so as to grind material particles with the thickness of more than 3 millimeters to 10-25 micrometers.
The diameter of the she-medicine phlegm-reducing ultra-fine powder patch is 3.7cm, the thickness of the she-medicine phlegm-reducing ultra-fine powder patch is 2mm, and the weight of each she-medicine phlegm-reducing ultra-fine powder patch traditional Chinese medicine ointment is 4g.
Clinical experimental data of she medicine phlegm-reducing ultra-fine powder patch
1. Case selection
78 patients with phlegm-heat obstructing lung type wind-warm lung-heat disease who meet the standard of the research are randomly divided into a control group and a test group, wherein the control group adopts conventional western medicine treatment and nursing; the test group carries out she-medicated phlegm-eliminating ultra-fine powder patch ultrasonic penetration treatment on Feishu acupoint, pishu acupoint and Shenshu acupoint on the basis of the control group. The intervention is performed 1 time per acupoint every day, and 10 days is a treatment course. Comparing the effectiveness of intervention of two groups of patients, and observing the change of each index of the patients before intervention, on the 5 th day of intervention and on the 10 th day of intervention.
2. Diagnostic criteria
2.1 Western diagnostic standards
Refer to the diagnostic criteria in "guidelines for diagnosis and treatment of acquired pneumonia in adult Community in China (2018 edition).
(1) The occurrence of community diseases. (2) pneumonia-associated clinical manifestations: (1) cough, expectoration, or aggravation of original respiratory diseases, with or without chest pain, purulent phlegm, dyspnea and hemoptysis; (2) generating heat; (3) pulmonary moist rales or signs of lung consolidation; (4) WBC lower than 4X 10 9 At a rate of more than 10X 10/L 9 L; (3) Chest imaging examination revealed newly appearing blotchy infiltrates, leaf or segment solid lesions, abrasions or interstitial changes with or without pleural effusion.
Meets any one of the items (1), (3) and (2), and can establish clinical diagnosis by excluding pulmonary tuberculosis, lung tumor, pulmonary embolism and the like.
2.2 Chinese medicine diagnostic Standard
Refer to "diagnostic criteria for wind-warm lung-heat disease" and "diagnostic efficacy criteria for internal medicine syndrome of traditional Chinese medicine" in the standards of the Chinese medical industry of the people's republic of China (ZY/T001.1-94); the diagnosis is based on (1) the main symptoms of fever, cough, polydipsia, or accompanied by shortness of breath and chest pain. (2) Severe cases may have symptoms such as high fever, flushed face, dysphoria, coma and delirium, and even cold limbs. (3) The disease is frequently developed in winter and spring, and has the characteristics of acute onset, rapid transmission and short course of disease. (4) Those with elevated total blood leukocytes and neutrophils are considered to be bacterial infections. (5) The lung may have excessive signs, or auscultation may be accompanied by dry or wet rales. (6) the pathogen can be detected by sputum smear or sputum culture. (7) Chest X-ray fluoroscopy or radiography shows inflammatory shadows of one or both lobes or segments.
2.3 syndrome type diagnostic criteria
The main symptoms are: cough, yellow or white, dry and sticky sputum. The secondary symptoms are as follows: fever, shortness of breath, poor appetite, cough, dyspnea, chest pain, fullness in the chest and hypochondrium, pain during cough, phlegm sound in the throat, sticky and yellow sputum, hypodynamia, red tongue with yellow coating, and slippery and rapid pulse. Can be diagnosed with 2 main symptoms or 1 main symptom plus 2 secondary symptoms.
3. Inclusion criteria
3.1 in accordance with the Chinese and Western diagnosis standards
3.2 patients with mild to moderate CAP
3.3 age 18-80 years old
3.4 operating site skin integrity without Damage
3.5 syndrome score is greater than or equal to 4 points and CPIS score is greater than or equal to 4 points
3.6 know this study and sign consent
4. Exclusion criteria
4.1 patients with severe primary diseases such as severe organ dysfunction, endocrine system, hemopoietic system, severe infection, and malignant tumor
4.2 patients with acute myocardial infarction, cardiogenic shock, severe ventricular arrhythmia, obstructive cardiomyopathy, unrepaired valvular disease, constrictive pericarditis, pericardial tamponade, pulmonary embolism
4.3 unstable angina pectoris or myocardial infarction occurring in approximately 1 month
4.4 pregnant or lactating women
4.5 those with a history of psychosis
4.6 drug allergy or contraindication
4.7 taking medicine affecting immunity function in nearly 3 months
4.8 compliance is poor, reject this study treatment more than or equal to 1 time
4.9 patients who were concurrently undergoing other trials
5. Index of end of falling
5.1 quit in the middle due to intolerance
5.2 Change of disease requires a transition
5.3 patients with drug allergy such as redness and pruritus
6. Grouping method
Random cards are made from a random number table generated by SPSS 23.0. Then the special person seals the random cards one by using the closed lightproof envelopes, randomly extracts the envelopes according to the test sequence of the tested patients, opens the envelopes under the evidence of the special person, and carries out grouping treatment according to the cards in the envelopes. It was divided into a control group and a test group. Baseline calibration was performed to ensure that there were no statistical differences between the two groups with respect to age, sex, smoking history, body mass index, underlying disease, etc. general data. And each group is intervened by a corresponding scheme and strictly executed.
7. Data collection method
Before intervention: the method comprises the steps of collecting baseline data before the formal start of intervention research, communicating two trained nurses (responsibility group leaders) with patients and family members to inform the research purpose, content and significance, collecting general data such as age, sex and body mass index of the patients face to face after the patients and the family members are matched and sign an informed consent, and collecting data such as traditional Chinese medicine syndrome points, lung infection CPIS scores and inflammatory indexes. When collecting data, the attention and the wording are unified and the patient fills in the words by himself; when the patient can not fill in the content by himself, the patient can be helped to complete the filling content through the forms of inquiry, explanation and the like.
Dry prognosis: data relating to the intervention on day 5 and day 10 were still collected by the two nurses.
8. Sample size estimation
The method comprises the steps of adopting PASSS15.0.5 software to estimate the sample amount, wherein alpha =0.1, beta =0.2, the ratio of the number of cases of a test group to the number of cases of a control group is 1, taking the effective rate as a main outcome index, calculating 68 samples which are needed by two groups in total according to the early-stage pre-experimental result (the effective rate of the test group is 90 percent, and the effective rate of the control group is 70 percent), considering that the 15 percent increase of the shedding rate is increased, and determining the sample amount as 78 samples, and each group comprises 39 samples.
9. Therapeutic material
The instrument comprises the following steps: an ultrasonic pulse conductance therapeutic apparatus SLC-005;
electrode for physical therapy: model ZDL-002 Sanlang brand electrode cotton sheet;
she medicine phlegm-reducing ultrafine powder plaster: the diameter is 3.7cm, the thickness is 2mm, and each tablet is about 4g.
10. Treatment and nursing method
10.1 control intervention protocol
Refer to Chinese adult CAP diagnosis and treatment guidelines (2018), published by the respiratory disease division of the Chinese medical society. Expectorant: carrying out intravenous drip of 15mg of ambroxol hydrochloride once a day; spasmolytic: doxofylline for injection 0.3g is instilled in the vein once a day; the nursing measures provide symptomatic nursing measures such as oxygen inhalation, temperature reduction, back patting, effective cough and expectoration guidance according to community acquired pneumonia nursing conventions, and western medicine nursing measures such as guidance of patients to drink more water, high-protein light diet, lip contraction and breathing, and mood keeping.
10.2 test group intervention protocol:
on the basis of the intervention scheme of a control group, she medicine phlegm-reducing submicron powder is adopted for being stuck on the acupuncture points for ultrasonic penetration.
10.2.1 intervention team construction and training
(1) Implementation personnel conditions: the medical nursing system has a class of subject group members which execute qualification by the traditional Chinese medicine nursing technology and uniformly trains and examines qualified persons.
(2) The theoretical training contents comprise the composition of the medicine, the positioning and the action of related acupuncture points, the acupuncture point locating method and the like. According to the composition of the medicines, by looking up the she nationality medicine and the Chinese pharmacology published by the Chinese traditional medicine publishing company and looking up the related documents, the data of the medicine name, the medicine property, the channel tropism, the main application method, the clinical use experience and the like of the medicines involved in the research are arranged for training; the method refers to the national standard of the people's republic of China, namely the name and location of acupoints (GB/T12346-2006) and the method for learning the location, action and acupoint selection of relevant acupoints of the teaching material meridian acupoints of the national colleges and universities of high-grade traditional Chinese medicine, such as the tenth edition of Chinese traditional medicine publishing society.
(3) Operation training
(1) The operation training is unified according to the operation scoring standard of 'ultrasonic drug penetration treatment', and a teacher is taught to fix one person, so that the training is a talent in the backbone of traditional Chinese medicine nursing in Zhejiang province.
(2) A she medicine phlegm-reducing ultra-fine powder patch is prepared by recording a video in a manufacturing process for learning; the operation processes of medicine mixing, dosing, coating and the like all need training and then pass examination, and work under the guidance of a professional quality controller (a pharmacist in the she medicine research institute).
(3) The nurse is required to perform skilled operation, the high-grade evaluation is passed, the accuracy of manufacturing the she-medicine phlegm-reducing submicron powder patch, acupoint selection, treatment and other key links is required to be 100%, and the person with the evaluation score of more than 95 is identified as having the implementation qualification of the research technology. Nurses who fail in one examination need to conduct examination again after intensive training, and if the nurses fail in three examinations, the nurses are not identified as operation qualified nurses.
10.2.2 preparation of she medicine phlegm-eliminating ultra-fine powder paste
The phlegm reducing ultra-micro powder patch is prepared by drying 50 parts by weight of she cold tea, 50 parts by weight of she melastoma, 15 parts by weight of ephedra herb, 30 parts by weight of almond, 15 parts by weight of rhizoma pinelliae preparata, 15 parts by weight of Chinese lute leaf, 10 parts by weight of borneol and 10 parts by weight of liquorice at the temperature of 60 ℃, mixing after superfine grinding, blending into an ointment by 45 parts by weight of honey, 50 parts by weight of water and 0.95 part by weight of she cold tea oil, coating the ointment on an ultrasonic guide cotton piece before use, and preparing the she medicine phlegm reducing ultra-micro powder patch.
10.2.3 implementation of the protocol
(1) Positioning
Positioning the acupoints: refer to the national standard of the people's republic of China, namely "name and location of acupoints" (GB/T12346-2006) and the textbook of the national colleges and universities of traditional Chinese medicine, namely, the tenth edition of the Chinese medicine publisher, namely "meridian and acupoint science".
Feishu acupoint: on the 3 rd thoracic vertebra, 1.5 cun lateral to the spinous process of the thoracic vertebra is the point of the lung where back shu points are located, shu is infused together, and this point is the point where lung qi is transported and infused, which is the important point for treating lung diseases. Has the functions of relieving exterior syndrome, dispersing lung qi, and descending lung qi.
Pishu points: 1.5 cun lateral to the spinous process of the thoracic vertebra 11, on the back Shu point of the spleen, it stimulates Pishu to strengthen the transportation and transformation of the spleen, and it has the actions of strengthening the spleen and resolving phlegm.
Shenshu points: 1.5 cun lateral to the spinous process of lumbar vertebra 2, it is the back Shu point of kidney, where essence and qi in kidney can defend the body, prevent invasion of pathogens, and prevent diseases.
(2) Intervention time: the test group was subjected to she-medicine ultrasonic penetration at 5 to 7. The lung is exterior-interior to the large intestine, and 5-00.
(3) Intervention method
(1) The patients were evaluated for major symptoms, past and allergic history, and pregnancy. Sensory perception and local skin condition. The notification time is typically 15 minutes, and slight needle and formication may occur during the treatment period, which is a normal phenomenon,
if the local part is burnt or the acupuncture feeling can not be resisted, a nurse is immediately informed.
(2) Article preparation
Ultrasonic medicine penetration therapeutic apparatus, physiotherapy sheet, bandage or elastic hasp, and adhesive plaster.
(3) Basic method of operation
Checking medical advice, evaluating a patient, making an explanation and adjusting the room temperature; the materials are carried to the bedside after being prepared. Assisting the patient to take a comfortable position and exposing the treatment part. Turning on a power switch, scooping out 4g of the prepared medicine by a quantitative spoon, uniformly coating the medicine on a special cotton piece, placing the special cotton piece on a treatment part, fixing, turning on a power supply, adjusting gears, and gradually changing from small to large until the medicine is suitable for a patient to endure. Patient experience is of concern during treatment. And (5) taking down the superfine powder to be pasted with the electrode after the treatment is finished, wiping the local skin, and observing the skin condition.
(4) Matters of attention
The treatment method is used cautiously for patients with metal foreign bodies at the treatment part and patients with a cardiac pacemaker; during treatment, people pay attention to shielding to protect privacy and keep warm; during the treatment process, the reaction of the patient and the machine operation condition need to be observed; the skin of the treatment part has red rash, pain, blisters and the like, and the treatment should be stopped immediately and the doctor should be informed to cooperate with the treatment; the treatment course is 1 time per day, 10 times is a course of treatment, and 1 course of treatment is total.
11. Adverse events
During the treatment process, whether the patient has discomfort such as skin redness and pruritus is concerned, the patient is definitely informed of any discomfort and needs to be informed to medical staff, and the medical staff judges whether to continue to participate in the research.
12. Criteria for evaluating therapeutic effects
Refer to Chinese adult CAP diagnosis and treatment guidelines (2018), to establish the standard. (1) curing: clinical symptoms and signs disappear or basically disappear, and inflammatory indexes such as WBC, N%, CRP, PCT and the like return to normal. (2) effect is shown: the clinical symptoms and signs are obviously improved, and the inflammatory indexes such as WBC, N%, CRP, PCT and the like are obviously reduced. (3) effective: the clinical symptoms and signs are improved, and the inflammatory indexes such as WBC, N%, CRP, PCT and the like are not obviously reduced. And (4) invalidation: the clinical symptoms and signs are unchanged or aggravated, and inflammatory indexes such as WBC, N%, CRP, PCT and the like are not reduced or aggravated. Note: total effective rate = (cure + show effect + effective)/total number of cases x 100%.
13. Quality control
13.1 screening the subjects strictly according to inclusion and exclusion criteria, following voluntary, confidential, non-injurious ethical principles.
13.2 the western medicine treatment schemes of the two groups of patients are consistent, and the phlegm-heat obstructing lung type wind-warm lung-heat disease nursing scheme is adopted for consistent nursing, so that the interference of mixed factors is reduced.
13.3, a unified operation standard of project operation is formulated, a project implementer is trained in a unified way, and the examination can be determined to carry out the technical implementation of the research after passing: nurses with operation qualification in departments are trained uniformly, and the operation can be performed after the examination. The quality control is carried out according to a daily operation implementation staff list, and two high-age nurses are responsible for quality supervision and control.
13.4 the evaluators carry out unified training, adopt unified standard to operate, reduce subjective bias: two responsibility group leaders are fixed to serve as evaluators for training, relevant data are evaluated, and the unification of standards is guaranteed.
And 13.5, implementing a blind method for the evaluator, namely, the evaluator does not know the test grouping condition of the patient, and performs data collection and evaluation according to the serial number of the patient as a unique number, so as to ensure the objectivity and the accuracy of the statistical result.
13.6 the she medicine phlegm-reducing ultra-fine powder paste is strictly prepared according to the program requirements, and various kinds of medicine ultra-fine powder and other substances such as water are mixed and uniformly mixed in the process and are all prepared according to the standard proportion. The previous low-temperature drying and medicine mixing are completed by the assistance of traditional Chinese medicine doctors of she-medicine research institute of Chinese medicine, chiense Zhang, zhejiang province, and the operation quality of the process is controlled.
13.7 patient compliance: the propaganda and education of the disease health knowledge of the patient are enhanced, so that the patient can realize the importance of the cooperative treatment; informing the principle and significance of the research and improving the adaptability of patients; the executive nurse is operated to verbally encourage the patient and give certain gift rewards on demand.
13.8 an emergency plan for adverse reaction after the she-nationality medicine phlegm-eliminating ultra-fine powder patch is made.
14. Statistical analysis
Statistical analysis was performed on the data of this study using SPSS23.0 statistical software. The result of the measured data is expressed by mean plus or minus standard deviation, the effect comparison of time and processing factors is carried out by adopting bidirectional repeated measurement variance analysis, the spherical hypothesis is verified by adopting Mauchly test, and if the spherical hypothesis is violated, the correction is carried out by adopting a Greenhouse-Geisser method. When there is an interactive effect, then a separate effect analysis is performed, using the Bonferroni method for post hoc analysis. Counting data are expressed by frequency and percentage, and analysis is carried out by chi-square test. And comparing between the grade data groups by adopting a rank sum test. By using a two-sided test, P < 0.05 indicates that the difference is statistically significant.
15. Ethical examination
The study passed the ethical examination of the ethical committee of the medical ethics of Lishu, TCM, subsidiary of Zhejiang university of medicine, ethical examination No. (2021) and clinical trial No. (LW-014) before being carried out, and all the subjects participated in the study after signing informed consent.
2. Results of the experiment
Comparison of baseline data between two groups of patients
In the research process, 1 case of the test group and 2 cases of the control group are dropped, 75 effective data are finally counted, and the dropping rate is 3.85%. The experimental group consisted of 38 men 20 and women 18 aged 33-76 years; the control group consisted of 37, 18 males and 19 females, aged 25-78 years.
Through statistical analysis, the difference between the two groups of patients in age, sex, body mass index, smoking history and the like has no statistical significance (P > 0.05) and is comparable. See table 1 for details.
TABLE 1 comparison of baseline data between two groups of patients
(II) Chinese medicine syndrome integral comparison of two groups of patients
Wind-warm lung-heat syndrome integral: the total of the three symptoms are cough expectoration, aversion to cold, fever and chest distress and pain, and the evaluation is carried out according to the actual condition of the patient, and the final product is the sum of the three scores.
Repeated determination and variance analysis show that the single effect analysis is carried out on the traditional Chinese medicine syndrome integrals due to the interactive effect (P is less than 0.05) existing in the intervention time and the group, and the result shows that the difference between the test group and the control group before intervention has no statistical significance (P = 0.864) and has comparability; along with the prolongation of the intervention time, the traditional Chinese medicine syndrome integrals of the test group and the control group are gradually decreased on the 5 th day and the 10 th day of the intervention, the difference has statistical significance (F =1618.890, P < 0.001), and the degree of reducing the traditional Chinese medicine syndrome integrals between the two groups is also obviously different (F =4.079, P < 0.05). In conclusion, the traditional Chinese medicine syndrome integrals of the two groups are gradually reduced along with the time, and the effect of improving the traditional Chinese medicine syndrome integrals of the test group is better than that of the control group. See table 2 for details.
TABLE 2 Chinese medicine syndrome integral comparison of two groups of patients: (
Minute)
Comparison of pulmonary infection CPIS scores in (III) two groups of patients
Pulmonary infection CPIS score: the system is a scoring system for evaluating the infection severity degree by integrating clinical, imaging and microbiological standards, and the highest score is 12; the higher the score the more severe the disease.
The repeated measures of anova show that the interaction effect exists between the intervention time and the groups (P is less than 0.05), so that the CPIS scores are subjected to independent effect analysis, and the results show that the difference between the CPIS scores before the two groups of interventions has no statistical significance (P = 0.544) and is comparable; the CPIS scores of the test and control groups decreased progressively with increasing intervention time, with statistical significance for the differences (F =2569.096, P < 0.001), and significant differences between the two groups (F =4.226, P < 0.05) in the degree of decrease in CPIS score. Taken together, the pulmonary infection CPIS scores for both groups decreased gradually over time, and the test group decreased better than the control group. See table 3 for details.
TABLE 3 comparison of CPIS scores for pulmonary infections in two groups of patients: (
Minute)
Comparison of inflammation indicators In (IV) two groups of patients
According to repeated determination of variance analysis, interactive effect exists between the intervention time and the group (P is less than 0.05), so that the individual effect analysis is carried out on the percentage of neutrophils (N%), the hypersensitivity C-reactive protein (CRP) and the procalcitonin value (PCT), and the result shows that the differences of N%, CRP and PCT in the two groups have no statistical significance (P is more than 0.05) before the intervention and are comparable; over time, the dry prognosis for both the test and control groups was decreased in N%, CRP, and PCT compared to pre-intervention, with statistical significance (mean P < 0.001), and significant differences between the two groups in the degree of decrease in CPIS score (mean P < 0.05). In conclusion, the inflammation index of the two groups gradually decreases with the time, and the decrease effect of the test group is better than that of the control group. See table 4 for details.
TABLE 4 comparison of inflammation indices in two groups of patients
(V) clinical efficacy comparison of two groups of patients
According to the clinical judgment standard, 35 patients in the test group are clinically effective, and the total effective rate is 92.11%; 30 patients in the control group are clinically effective, the total effective rate is 81.08%, the clinical curative effect of the two groups of patients has statistical significance, and the curative effect of the test group is superior to that of the control group (Z =2.329, P = 0.020), which is shown in Table 5.
TABLE 5 comparison of clinical efficacy of two groups of patients [ case (%) ]
(VI) evaluation of safety
During the study, the control group fell off 2 cases and the test group fell off 1 case. The patients in the test group had reddened skin on day 3, were disinfected with iodophor cotton swabs, and then were gently wiped with a cotton swab of 0.9% saline for 1 day and 2 times, and returned to normal on day 5, so the test was discontinued and the nurse continued to follow the skin condition.
3. Analysis of the results of the study
According to the study, the results of comparison between the test group and the control group intervening the 5 th day and the 10 th day are shown, the traditional Chinese medicine syndrome integral, the lung infection CPIS score, the neutrophil percentage, CRP and procalcitonin have statistical significance (P is less than 0.05) in comparison of the difference between the groups, and the she-medicine phlegm-resolving submicron powder is pasted on the submicron powder through acupoint ultrasonic penetration treatment, so that the she-medicine phlegm-heat obstructing lung type wind-warm lung heat disease patient has a good treatment effect;
the comparison of the two groups of curative effects shows that the total effective rate of the test group is 92.11 percent; the total effective rate of the control group is 81.08 percent, and the curative effect of she medicine on the phlegm-heat obstructing lung type wind-warm lung-heat disease by ultrasonic penetration through acupuncture points is better than that of the control group (Z =2.329, P = 0.020). The ultrasonic medicine penetration therapy is to enhance the transdermal transmission of a plurality of medicines including macromolecular medicines, improve the skin penetration capability, increase the local medicine concentration and better exert the medicine effect of she medicine.
In conclusion, the curative effect of she medicine phlegm-resolving submicron powder for treating phlegm-heat obstructing lung type wind-warm lung-heat disease patients by ultrasonic penetration on acupuncture points is superior to that of the conventional western medicine treatment and nursing.
2. She medicine phlegm-resolving ultra-micro powder paste ultra-micro powder acupoint ultrasonic penetration treatment intervenes for phlegm-heat obstructing lung type wind-warm lung-heat disease for 10 days better than 5 days
The difference of the two groups of patients compared with each other at three time points of traditional Chinese medicine syndrome integration, CPIS score, neutrophil percentage, hypersensitive C reactive protein and procalcitonin has statistical significance (P is less than 0.001). The she medicine phlegm-reducing ultrafine powder is applied to acupuncture points for ultrasonic penetration treatment, so that the traditional Chinese medicine syndrome integral and CPIS score can be reduced, and the neutral granulocyte percentage, the hypersensitive C-reactive protein, the procalcitonin and the like in blood can be reduced. Meanwhile, the time effect comparison of the indexes of 10 days of intervention and 5 days of intervention is carried out, and the result shows that the indexes of 10 days of intervention are superior to the indexes of 5 days of treatment. The results show that the she-medicine phlegm-reducing submicron powder has more sufficient curative effect on patients undergoing channel-acupoint ultrasonic penetration treatment and more obvious traditional Chinese medicine effect along with the prolongation of the intervention time.
4. Conclusion
The she medicine phlegm-reducing formula submicron powder acupoint ultrasonic penetration can obviously improve the traditional Chinese medicine syndrome integral of a patient suffering from phlegm-heat obstructing lung type wind-warm lung-heat, effectively reduce the CPIS score of the lung infection of the patient and related inflammatory indexes (N%, CRP and PCT), effectively improve the clinical curative effect, and is worthy of clinical popularization and application.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that are within the spirit and principle of the present invention are intended to be included in the scope of the present invention.
Claims (4)
1. A she medicine phlegm-reducing submicron powder patch is characterized in that the she medicine phlegm-reducing submicron powder patch comprises the following medicine components in parts by weight: 45-55 parts of herb tea (she), 45-55 parts of Chinese prickly ash (she), 10-20 parts of ephedra, 25-35 parts of almond, 10-20 parts of ginger processed pinellia tuber, 10-20 parts of Chinese lute leaf, 5-15 parts of borneol and 5-15 parts of liquorice.
2. The she medicine phlegm-eliminating ultra-fine powder paste as claimed in claim 1, wherein the she medicine phlegm-eliminating ultra-fine powder paste comprises the following medicinal components in parts by weight: 50 parts of herb tea (she), 50 parts of herba rhodomyrti (she), 15 parts of ephedra, 30 parts of almond, 15 parts of rhizoma pinelliae preparata, 15 parts of Chinese lute leaf, 10 parts of borneol and 10 parts of liquorice.
3. A preparation method of a she medicinal phlegm-reducing ultra-fine powder patch is characterized in that the she medicinal phlegm-reducing ultra-fine powder patch in claim 2 is dried at the temperature of 60 ℃, is subjected to ultra-fine grinding and then is mixed, and is blended into ointment by 45 parts of honey, 50 parts of water and 0.95 part of cold tea oil by weight, and the ointment is coated on an ultrasonic guided cotton piece before use to be prepared into the she medicinal phlegm-reducing ultra-fine powder patch.
4. The preparation method of the she-medicine phlegm-resolving ultra-fine powder patch as claimed in claim 3, wherein the diameter of the she-medicine phlegm-resolving ultra-fine powder patch is 3.7cm, the thickness of the she-medicine phlegm-resolving ultra-fine powder patch is 2mm, and the weight of the she-medicine phlegm-resolving ultra-fine powder patch Chinese medicinal ointment is 4g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211346714.9A CN115634250B (en) | 2022-10-31 | 2022-10-31 | She medicine phlegm-resolving superfine powder patch and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211346714.9A CN115634250B (en) | 2022-10-31 | 2022-10-31 | She medicine phlegm-resolving superfine powder patch and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115634250A true CN115634250A (en) | 2023-01-24 |
| CN115634250B CN115634250B (en) | 2023-06-20 |
Family
ID=84946175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211346714.9A Active CN115634250B (en) | 2022-10-31 | 2022-10-31 | She medicine phlegm-resolving superfine powder patch and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115634250B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104721429A (en) * | 2015-03-27 | 2015-06-24 | 福建省漳州市中医院 | Chinese medicinal externally-used patch for treating cough and asthma due to accumulation of phlegm and heat in lung and preparation method thereof |
| CN105267522A (en) * | 2015-11-23 | 2016-01-27 | 许世钦 | Phlegm reducing patch for treating cough and asthma |
-
2022
- 2022-10-31 CN CN202211346714.9A patent/CN115634250B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104721429A (en) * | 2015-03-27 | 2015-06-24 | 福建省漳州市中医院 | Chinese medicinal externally-used patch for treating cough and asthma due to accumulation of phlegm and heat in lung and preparation method thereof |
| CN105267522A (en) * | 2015-11-23 | 2016-01-27 | 许世钦 | Phlegm reducing patch for treating cough and asthma |
Non-Patent Citations (1)
| Title |
|---|
| 范蕾等: "12种畲药的研究进展", 中国药师, vol. 19, no. 07, pages 1374 - 1377 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115634250B (en) | 2023-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Bu-Fei Yi-Shen granule combined with acupoint sticking therapy in patients with stable chronic obstructive pulmonary disease: a randomized, double-blind, double-dummy, active-controlled, 4-center study | |
| Zhao et al. | Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a | |
| CN103961415A (en) | Crude herb moxybustion cataplasm and preparation method thereof | |
| Li et al. | Clinical practice guidelines and experts’ consensuses for treatment of coronavirus disease 2019 (COVID-19) patients with Chinese herbal medicine: a systematic review | |
| CN101843840B (en) | Chinese medicinal compound granules for treating acute exacerbation of chronic obstructive pulmonary disease | |
| CN115634250A (en) | She medicine phlegm-reducing ultrafine powder patch and preparation method thereof | |
| CN100553666C (en) | Medicine of treatment chronic pulmonary heart disease and preparation method thereof | |
| CN113648378B (en) | Traditional Chinese medicine compound for treating early stage neocoronary pneumonia and application of traditional Chinese medicine compound for treating respiratory tract infection | |
| CN110170035B (en) | Pharmaceutical composition for treating psoriasis vulgaris, pharmaceutical preparation and application | |
| CN112138084A (en) | Traditional Chinese medicine formula for treating bronchiectasis syndrome of qi-yin deficiency and phlegm-heat obstructing lung and application thereof | |
| CN104940304A (en) | Application for treating childhood asthma in remission phase through iontophoresis | |
| CN104958727A (en) | Traditional Chinese medicine composition for treating pediatric asthma in paracmasia and application of traditional Chinese medicine composition | |
| CN112138105B (en) | Traditional Chinese medicine composition for treating bronchiectasis lung-spleen qi deficiency and phlegm-damp lung blocking syndrome and application thereof | |
| Liu et al. | [Retracted] Efficacy and Safety of Rupatadine Fumarate Combined with Acupoint Application in Allergic Rhinitis Complicated with Diabetes | |
| CN106214770B (en) | Application of collateral activating and pain relieving capsule in preparation of medicine for treating diabetic peripheral neuropathy | |
| CN104906207B (en) | It is a kind of prevent Chronic Obstructive Pulmonary Disease breaking-out outer control drug and preparation method thereof | |
| Jurecek et al. | Beneficial effects of an alkaline topical treatment in patients with mild atopic dermatitis | |
| CN116270839B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and ankylosing spondylitis as well as preparation method and application thereof | |
| CN101991730A (en) | Traditional Chinese medicine compound preparation for treating bronchial asthma and resisting recurrence and preparation method thereof | |
| Wu et al. | Efficacy Analysis of Wandai Decoction Combined with Traditional Chinese Medicine Fumigation and Washing in Patients with Chronic Vaginitis After Sintilimab Treatment for Small Cell Lung Cancer. | |
| CN103721019B (en) | A kind of Chinese medicine composition improving rheumatoid arthritis | |
| CN107050340B (en) | Traditional Chinese medicine composition for treating necrotizing lymphadenitis and application thereof | |
| CN107158167B (en) | Traditional Chinese medicine film for treating necrotizing lymphadenitis and preparation method thereof | |
| CN107569655A (en) | A kind of Chinese medicine composition for acute exacerbation of chronic obstructive pulmonary disease | |
| CN106075334A (en) | A kind of compositions purposes in auxiliary treatment infantile eczema |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |